FDAbriefings.

Aerial view of three distinct currents flowing side by side without merging, symbolizing separate regulatory tracks that have not yet converged.

The Convergence Gap in AI Life Sciences Regulation

Regulators describe AI, digital health, and clinical trial law as converging, but FDA, UK, and Chinese actions show the frameworks are still moving on separate, misaligned tracks.

A single strand of DNA reflected through a fractured mirror into three diverging paths of light, symbolizing regulatory divergence.

AI Governance's Real Fault Line Is Classification, Not Geography

Divergence in AI rules across the US, EU, and China is driven less by geography than by conflicting definitions of what counts as a regulated AI function.

A glowing server rack seen through frosted glass from a hospital corridor, symbolizing the divide between infrastructure architecture and clinical decision-making.

Clinical AI's Accuracy Question Was Never the Whole Question

FDA's own framework gaps show interaction risk matters as much as accuracy, but the on-premise architecture fix now circulating is a contested proposal, not a settled control.

A translucent boundary of light dividing a hospital corridor, symbolizing the uneven regulatory perimeter around clinical AI.

The Clinical AI Governance Gap Is Structural, Not Accidental

The regulatory perimeter around clinical AI is contested by design, and the same gap is opening upstream in drug development.

Three cracked glass panes under clinical light, symbolizing regulatory categories fracturing under new AI health technologies.

Health AI Is Straining Categories, Not Just Rules

US data provenance, UK product classification, and Chinese jurisdictional scope are all cracking under AI health tools that don't fit pre-AI regulatory taxonomy.

A hospital records archive and a glowing server rack stand apart across a shadowed floor, symbolizing the gap between device paperwork and generalist AI capability.

The Benchmarking Gap FDA Hasn't Closed

Nature Medicine's new framework for evaluating generalist medical AI outpaces FDA's device-modification tools, leaving capability-tier governance to buyers.

A digital medical record shown crossing from a secure vault into open, unprotected space, illustrating data leaving regulatory coverage.

Your Patients Are Uploading Health Data Into a Regulatory Gap

Life sciences firms building patient-facing AI tools are relying on a HIPAA and FDA perimeter that consumer health AI routinely sits outside.

A stationary regulatory rulebook against a blur of fast-moving digital data trails, symbolizing regulation lagging AI velocity.

The Guidance Cannot Outrun the Model

FDA and EU regulators are structurally too slow to govern AI at the pace it changes, so life sciences compliance leaders must build internal governance now.

Robotic arm in a factory with layered digital compliance seals stacked above it, representing multiple overlapping certification requirements.

Machine Safety Certification Is Becoming a Stack, Not a Stamp

Industrial AI systems now need functional safety, AI governance, and sector regulation layered together, and buyers should verify each layer separately.

A hospital corridor with faint glowing light trails behind the walls, symbolizing unseen AI systems operating inside clinical infrastructure.

The Governance Gap FDA's Rulemaking Won't Reach

FDA is still asking questions about generative AI in medicine while health systems already run it inside clinical workflows unmonitored.

Illustration of patient health data flowing from a regulated zone into an unregulated open space.

When Health Data Leaves the Regulated Perimeter

FDA's wellness classification determines more than marketing claims. It decides whether patient data uploaded to AI tools carries any regulatory protection at all.